Emergent BioSolutions | EBS - 税前利润



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 251.6M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


税前利润 更改 日
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 40.22M 8.74M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Exelixis USD 262.68M 5.01M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114M 21M 2026-06
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Lonza CHF 624M 197M 2024-12
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Myriad Genetics USD 4.6M 3.4M 2025-12
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pacira USD 5M 4.43M 2026-03
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sanofi EUR 837M 1.17B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
United Therapeutics USD 372.7M 54.4M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12